亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

濟南惠誠醫藥科技有限公司  

生產和銷售各類原料藥及其中間體,如:奧利司他、新利司他、利拉列汀、曲格列汀琥珀酸鹽、苯甲酸阿格列汀、卡格列凈半水合物、磷酸奧司他韋、瑞舒伐他汀鈣及其中間體、磷酸肌酸二鈉鹽、阿地溴銨、噻托溴銨一水合物、依替唑侖、丙戊酸鈉、美沙拉嗪、腎上腺素系列等。

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:趙攀峰
  • 電話:0531-68659623
  • 郵件:sales@hc-pharm.com
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 1R,2S-2-(3,4-二氟苯基)環丙胺 (R)-扁桃酸鹽
1R,2S-2-(3,4-二氟苯基)環丙胺 (R)-扁桃酸鹽
單價 面議對比
詢價 暫無
發貨 山東濟南市付款后3天內
品牌 惠誠
過期 長期有效
更新 2017-07-19 09:59
 
詳細信息

中文名稱: (1R,2S)-2-(3,4-二氟苯基)環丙胺 (R)-扁桃酸鹽

中文同義詞: 反式(1R,2S)-2- (2,3-二氟苯基)環丙胺扁桃酸鹽;(1R,2S)-2-(3,4-二氟苯基)環丙胺 (R)-扁桃酸鹽;替卡格雷中間體4;(1R,2S)-2-(3,4-二氟苯基)環丙胺扁桃酸鹽;(1R,2S)-2-(3,4-二氟苯基)環丙胺扁桃酸鹽(替卡格雷中間體);(1R)-2-(3,4-二氟苯基)環丙胺扁桃酸鹽;(1S,2R)-2-(3,4-二氟苯基)環丙胺扁桃酸鹽(替卡格雷中間體);替卡格雷中間體環丙胺

英文名稱: (1R,2R)-2-(3,4-difluorophenyl)cyclopropanamine(S)-(carboxylato(phenyl)methyl)holmium

英文同義詞: (1R,2R)-2-(3,4-difluorophenyl)cyclopropanamine(S)-(carboxylato(phenyl)methyl)holmium;trans-(1R,2S)-2-(2,3-difluorophenyl)cyclopropylaMine Mandelat;(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate;(alphaR)-alpha-Hydroxybenzeneacetic acid *pd. with (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine;(αR)-(1R,2S)-α-hydroxy-Benzeneacetic acid-*pd.with 2-(3,4-difluorophenyl)cyclopropanaMine(1:1);Ticagrelor InterMediate 4;(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaMine (2R)-Hydroxy(phenyl)ethanoate;(αR)-α-Hydroxybenzeneacetic Acid *pd. with (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaMine

CAS: 376608-71-8

分子式: C17H17F2NO3

分子量: 321.3185864

用途:替卡格雷中間體

©2025 濟南惠誠醫藥科技有限公司 版權所有   技術支持:化工網   訪問量:11464  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |